Loading...
•
Mar 31, 2023
Regulus Therapeutics Q1 2023 Earnings Report
Regulus Therapeutics reported financial results for Q1 2023 and provided a corporate update.
Key Takeaways
Regulus Therapeutics reported a net loss of $7.1 million, or $0.42 per share, for the first quarter ended March 31, 2023. The company's cash and cash equivalents were $30.3 million as of March 31, 2023, which is expected to extend into mid-2024 with the $15.0 million private placement.
Enrollment completed in first cohort of patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) in Phase 1b Multiple-Ascending Dose (MAD) study of RGLS8429.
Closed $15.0 million private placement of equity, expected to extend cash runway into mid-2024.
Research and development expenses were $4.9 million for the three months ended March 31, 2023.
Net loss was $7.1 million, or $0.42 per share, for the three months ended March 31, 2023.
Regulus Therapeutics
Regulus Therapeutics
Forward Guidance
Regulus anticipates that the $15 million private placement will extend their cash runway into mid-2024 and through several additional program milestones.